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Abstract
Cost is a key concern in fluid management. Relatively few data are available that address the
comparative total costs of care between different fluid management regimens in particular
clinical indications. Relevant costs of fluid-associated morbidity and mortality, including
those incurred after intensive care unit or hospital discharge, also need to be considered in
evaluating the cost–benefit ratios of administered fluids. Rigorously designed
pharmacoeconomic studies are needed to delineate the costs and benefits of various
approaches to fluid management.
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HES = hydroxyethyl starch; RCT = randomized controlled trial.
http://ccforum.com/content/4/S2/S33
The controversy surrounding choice of resuscitation fluid
owes much of its intensity and longevity to economic con-
cerns, yet reported pharmacoeconomic data comparing
costs of various fluid regimens are remarkably limited. The
expenditures for one fluid have typically been compared
with those for another when cost data have been reported
[1–3]. These data have rarely rigorously addressed the
comparative total costs of care taking into account poten-
tial differences in outcomes such as morbidity, mortality
and length of intensive care unit or hospital stay. Conse-
quently, the available pharmacoeconomic evidence to date
unfortunately fails to provide a solid foundation upon
which to rest clinical decision-making.
It will ultimately be necessary to define cost–benefit ratios
with specific reference to particular clinical indications and
fluid management regimens. In one randomized control
trial (RCT), for example, acute albumin administration in
hospitalized cirrhotic patients with ascites significantly
shortened hospital stay and reduced total costs of care by
nearly 60% [4]. Chronic albumin administration on an out-
patient basis, however, did not afford a similarly favourable
cost–benefit ratio.
Albumin stands centre stage in the debate over fluid
management costs. This natural colloid has been reported
to account for a substantial fraction of the pharmacy
budget at some hospitals. Some clinical investigations
have failed to provide evidence of significant patient
benefit associated with albumin administration [5–8].
Such lack of benefit coupled with the comparatively high
unit dose cost of this colloid has often prompted calls for
the abandonment of albumin in fluid management. The
RCTs of albumin administration reported to date have
nevertheless typically involved quite small numbers of
patients and were accordingly statistically underpowered
to detect differences in clinically relevant endpoints such
as morbidity, mortality and length of stay.Critical Care    Vol 4 Suppl 2 Vincent
Indeed, not a few studies have revealed significant differ-
ences favouring albumin in these clinically relevant end-
points. A recent RCT of patients with cirrhosis and
spontaneous bacterial peritonitis has attracted consider-
able notice in this regard [9]. Both mortality and incidence
of renal impairment were significantly reduced by albumin
administration. The incidence of renal impairment or
severe hyponatraemia in an earlier RCT of cirrhotic
patients with tense ascites was significantly lower in
patients treated by therapeutic paracentesis with versus
without albumin infusion [10]. Development of either or
both of these complications was significantly predictive of
higher actuarial mortality rate.
Such differences favouring albumin are not restricted to
cirrhosis. Addition of albumin to the priming solution in a
RCT of patients undergoing cardiopulmonary bypass
surgery was associated with a significant 34% reduction
in mediastinal blood loss during the first 12h postopera-
tively [11]. Furthermore, substitution of hydroxyethyl starch
(HES) for albumin as the cardiopulmonary bypass priming
fluid in a retrospective case–control study involving 288
patients, intended as a cost-saving measure, was associ-
ated with a dose-dependent increase in incidence of
haemorrhage [12]. The US$3458 median unadjusted hos-
pital cost associated with treatment of haemorrhage in
these patients was far greater than the difference in cost
between HES and albumin.
Hypovolaemic and septic shock, gastrointestinal surgery
and hypoalbuminaemia are additional indications in which
RCTs have provided evidence of significant benefit due to
albumin administration. The incidence of pulmonary
oedema, based upon radiographic evidence, was signifi-
cantly four-fold greater for the saline than either the
albumin or HES groups in a RCT of 26 patients with hypo-
volaemic and septic shock [13]. The severity of intestinal
oedema during gastrointestinal surgery in a RCT of 18
patients was significantly less among recipients of albumin
than of either Ringer’s lactate or HES [14]. The total
number of complications among 61 hypoalbuminaemic
patients enrolled in a RCT of albumin supplementation
was significantly greater by 136% in control than albumin
patients, and the number of control patients experiencing
complications was significantly greater by 44% [15]. Fur-
thermore, the numbers of control patients developing sep-
ticaemia and pneumonia were significantly greater than
those of the albumin group.
The unanswered question, of course, is the extent to
which such differences in morbidity would affect the
cost–benefit ratio of albumin. At a minimum, however,
these differences suggest that, in certain indications and
with certain administration regimens, the benefits of
albumin may well justify its costs.
Another factor that needs to be considered is the time
horizon for assessing total costs of care. Delayed morbid-
ity and mortality occurring after discharge might contribute
substantially to the total costs of care, although such
added costs have seldom been addressed in clinical
investigations thus far. In the RCT of Sort et al [9], for
instance, the total hospital mortality rate for both the
albumin and control groups together was 19%. An addi-
tional 13% of patients had, however, died by 3 months.
Delayed severe persistent pruritus, most commonly mani-
fested as pruritic crisis, has been reported in 32% of
patients receiving extended HES treatment [16]. Such
pruritus was encountered, on average, 25 days after com-
mencement of treatment, and pruritus developed in the
majority of patients after HES administration was discon-
tinued. The repercussions of fluid therapy may extend to
even longer time periods. In a renal transplantation study
of 438 patients, for instance, intraoperative albumin
administration was associated with a dose-dependent
reduction in frequencies of delayed or absent periopera-
tive graft function and a significantly higher graft survival
rate at 1 year postoperatively [17]. Late morbidity and
mortality after discharge from the intensive care unit or
hospital can clearly impose additional costs that should be
taken into account.
The current pharmacoeconomic picture of fluid manage-
ment is very far from complete. There is little doubt that
further studies are needed to establish the cost–benefit
ratio of particular fluid administration regimens in specified
clinical indications. The focus of such studies needs to be
on the total costs of care.
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